Section Review Central & Peripheral Nervous Systems: New antidepressant agents: Recent pharmacological developments leading to improved efficacy

References

• GOODWIN FK, JAMISON KR: Manic-Depressive Illness. Ox-ford University Press, New York, Oxford (1990).
   Google Scholar
• GOODNICK PJ, EXTEIN IL: Bupropion and fluoxetine indepressive subtypes. Ann. Chn. Psychiatry (1989) 1:119–122.
   Google Scholar
• ROSENBAUM JF, FAVA M, QUITKIN FM, FAWCETT J, AM-STERDAM J, REIMHERR FW, BEASLEY CM, Jr.: Time to remission of depression with acute fluoxetine treat-ment. Abstracts of 34th Annual Meeting NCDEU Marco Island, Florida, May 31 -June 3, 1994.
   Google Scholar
• FEIGHNER JP: The role of venlafaxine in rational anti-depressant therapy. J. Chn. Psychiatry (1994) 55(9 Suppl. A):62–68.
   Google Scholar
• RICHELSON E: Pharmacology of antidepressants - char-acteristics of the ideal drug. Mayo Chn. Proc. (1994) 69:1069–1081.
   PubMed Web of Science ®Google Scholar
• CUSAK B, NELSON A, RICHELSON E: Binding of antide-pressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (1994) 230:94–102.
   Google Scholar
• PRESKORN SIT, JANICAK PG, DAVIS JM, AYD FJ, Jr.: Ad-vances in the pharmacotherapy of depressive disor-ders. In: Principles and Practice ofPsychopharmacotherapy. Janicak PG (Ed.). Williams & Wilkins, New York (1995).
   Google Scholar
• NEMEROFF CB: Evolutionary trends in the pharma-cotherapeutic management of depression. (1994) 55(12 Suppl.):3–15.
   Google Scholar
• BARR LC, GOODMAN WK, MCDOUGLE CJ: Tryptophandepletion in patients with obsessive-compulsive disor-der who respond to serotonin reuptake inhibitors. Arch. Gen. Psychiatry (1994) 51:309–317.
   PubMed Web of Science ®Google Scholar
• JENIKE MA, HYMAN S, BAER L: A controlled trial of fluvoxamine in obsessive-compulsive disorder. Am. J. Psychiatry (1990) 147:1209–1215.
   PubMed Web of Science ®Google Scholar
• GOODNICK Pj: Pharmacokinetic optimisation of ther-apy with newer antidepressants. Clin. Pharrnacokinet. (1994) 27(4):307–330.
   PubMed Web of Science ®Google Scholar
• GOODNICK PJ: Newer antidepressants. In: Predictors of Treatment Response in Mood Disorders. Goodnick PJ (Ed.). APPI, Washington & London (1995).
   Google Scholar
• GOODNICK PJ, HENRY JH, BUM VMV: Treatment of depression in patients with diabetes mellitus. J. Clin. Psychiatry (1995) 56(4):128–136.
   PubMed Web of Science ®Google Scholar
• GOODNICK PJ, SANDOVAL R: Psychotropic treatment of chronic fatigue syndrome and related disorders. J. Chn. Psychiatry (1993) 54:13–20.
   PubMed Web of Science ®Google Scholar
• SHARPLEY AL, COWEN PJ: Effect of pharmacologic treat-ments on the sleep of depressed patients. Biol. Psychiatry (1995) 37:85–98.
   PubMed Web of Science ®Google Scholar
• DEVANE CL: Pharm,acoldnetics and drug metabolism of newer antidepressants. J. UM. Psychiatry (1994) 55(12 Suppl.):38–45.
   Google Scholar
• POLLOCK BG: Recent developments in drug metabolism of relevance to psychiatrists. ilarvard Rev. Psychiatry (1994) 2:204–213.
   PubMed Web of Science ®Google Scholar
• BENNIE EH, MULLIN JM, MARTINDALE jj: A double-blindmulticenter trial comparing sertraline and fluoxetine In outpatients with major depression. J. Clin. Psychiatry (1995) 56(6):229–237.
   PubMed Web of Science ®Google Scholar
• GREIST J, CHOUINARD G, DUBOFF E: Double-blind par-allel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive dis-order. Arch. Gen. Psychiatry (1995) 52:289–295.
   PubMed Web of Science ®Google Scholar
• 'WINOKUR A, LEXOW N, ALLEN K, REED D, BREITMEYER W: Sertraline administration for eight weeks to de-pressed patients did not alter sleep architecture: A preliminary report. New Research, Annual Meeting of American Psychiatric Association. May 21–26, 1994:110, #NR212.
   Google Scholar
• HINDMARCH I, KERR J: Behavioral toxicity of antidepres-sants with particular reference to moclobemide. Psycho-pharmacology (1992) 106:S49–S55.
   PubMed Web of Science ®Google Scholar
• GOODNICK PJ, HENRY J, KUMAR A: Neurochemistry and paroxetine response in major depression. Biol. Psychia-try (1995) 37:417–419.
   PubMed Web of Science ®Google Scholar
• OSWALD I, ADAM K: Effects of paroxetine on human sleep. J. Clin. Pharmac. (1986) 22:97–99.
   Web of Science ®Google Scholar
• GOODNICK PJ, SANDOVAL R, BRICKMAN A, KLIMAS N:Bupropiort treatment of ffuoxetine-resistant chronic fatigue syndrome. Biol. Psychiatry (1992) 32:834–838.
   PubMed Web of Science ®Google Scholar
• NOFZINGER EA, REYNOLDS CF Ill, THASE ME, FRANK E, JENNINGS JR, FASICZKA AL, SULLIVAN LR, KUPFER DJ: REM sleep enhancement by bupropion in depressed men. Am. J. Psychiatry (1989) 1:119–122.
   Google Scholar
• LECRUBIER Y: Antidepressant Drugs: similar but differ-ent? In: New Pharmacological Approaches to the Therapy of Depressive Disorders. Karger, Basel, Freiburg, Paris, London, New York, New Delhi, Bangkok, Singapore, Tokyo, Sydney (1992).
   Google Scholar
• NIERENBERG AA, FEIGHNER JP, RUDOLPH RR, COLE JO:Venlafaxine for treatment-resistant depression. Abstracts & Proceedings Summary 147th Annual Meeting American Psychiatric Association, May 1995:97–98, #68.
   Google Scholar
• GOODNICK PJ: Venlafaxine in chronic fatigue syn-drome. Am J. Psychiatry (1995). In press.
   Google Scholar
• MINOT R: Neurophysiological, longitudinal, placebo-controlled study of venlafaxine in depressed inpatients. Clin. Neuropharm. (1992) 15\(Suppl. 1, Part B):322B.
   Google Scholar
• SHARPLEY AL, WALSH AES, COWEN PJ: Nefazodone - a novel antidepressant - may increase REM sleep. Biol. Psychiatry (1992) 31:1070–1073.
   PubMed Web of Science ®Google Scholar
• ARMITAGE R, RUSH AJ, TIVEDI M, CAIN J, ROFFWARG HP: The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacot. (1994) 10(2):123–127.
   PubMed Web of Science ®Google Scholar
• MURPHY DL, MITCHELL PB, P01 LER WZ: Novel pharma-cological approaches to the treatment of depression. In: Psychopharmacology The Fourth Generation of Progress. Blood FE, Kupfer DJ (Eds.). Raven Press, New York (1995).
   Google Scholar
• JEFFERSON JW, GREIST JH: Psychopharmacology: A look to the future. In: Annual of Drug Therapy, Volume 1. Jefferson JW, Greist JH (Eds.). WB Saunders, Philadelphia, London, Toronto, Montreal, Sydney, Tokyo (1994).
   Google Scholar
• GUELFI JD: Efficacy of tianepthte in comparative trials versus reference antidepressants: An overview. Br. J. Psychiatry (1992) 160\(Suppl. 15):72–75.
   Google Scholar
• WARRINGTON SJ: Cardiovascular and anticholinergic effects of repeated doses of femoxitine - a comparison with amitriptyline and placebo in healthy men. Br. J. Clin. Pharmacol. (1989) 27:343–351.
   PubMed Web of Science ®Google Scholar
• ANGEL I, SCHOEMAKER H, PROUTEAU M: Litoxetine: aselective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur. J. Pharmacol. (1993) 232:139–145.
   PubMed Web of Science ®Google Scholar
• WILCOX C, COHN J, FERGUSON J, DALE J, FABRE L: A double-blind multicenter trial of a low dose range and high dose range of gepirone ER compared to placebo In the treatment of depressed outpatients. Abstracts of 35th Annual Meeting NCDEU May 1995, Orlando, Florida.
   Google Scholar
• HELLER All, BENEKE M, KUEMMEL B, SPENCER D, KURTZ NM: Ipsapirone: Evidence for efficacy in depression. Drug Lit. (1990) 26:219–222.
   Google Scholar
• DELAUNAY J, MEYNARD J, ELIE JC: Medifoxamine 50, an antidepressant drug without atropine-like side-effects. Ann. Med. Psycho!. (1982) 140:148–156.
   PubMedGoogle Scholar
• OSMAN OT, ET AL.: Personal communication.
   Google Scholar
• HALLIDAY CA, JONES BJ, SKINGLE M, WALSH DM, WISE H, TYERS MB: The pharmacology of fluparoxan: a selec-tive au-adrenoceptor antagonist. Br.J. Pharmacol. (1993) 35:1–7.
   Google Scholar
• ECKMANN F: Rolipram in major depression: results ofa double-blind comparison with amitriptyline. Curr. Ther. Res. (1988) 43:291–295.
   Web of Science ®Google Scholar